July 15, 2010 (FinancialWire) (Go to http://www.financialwire.net/?s=ftrdnwswnd for all of today’s featured news.) — Cell Therapeutics (NASDAQ: CTIC) said that it has signed a manufacturing agreement with NerPharMa DS, a pharmaceutical manufacturing company belonging to Italy-based Nerviano Medical Sciences S.r.l., for CTI's drug candidate pixantrone.

The five-year contract between CTI and NerPharMa provides for both the commercial and clinical supply of pixantrone.

CTI is developing pixantrone as a treatment option for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. CTI is currently preparing to submit a Marketing Authorization Application in the European Union, and plans to initiate a Phase III trial of pixantrone in patients with relapsed or refractory aggressive NHL in the U.S. Both are planned for this year.

CTI reported on June 14, 2010 that the Italian Medicines Agency, the national authority responsible for drug regulation in Italy, had approved the facility at NerPharMa for the production of pixantrone.

Nerviano Medical Sciences is a pharmaceutical research and development facility in Italy and one of the largest oncology-focused, integrated discovery and development companies in Europe.

Washington-based Cell Therapeutics is a biopharmaceutical company committed to developing an integrated portfolio of oncology products.

Real-time, streaming research for companies and funds mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate (at http://investrend.stocksmart.com/ss/html/hpcompany.html). Current valuation analysis research for companies and funds mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate (at http://www.valuengine.com/rep/searchsrep?pid=42&srchfor=).

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public other companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (at http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation from subject entities, companies, equities, or representatives thereof, for its news, opinions or distributions. Further disclosure is posted at the FinancialWire(tm) website (at http://www.financialwire.net/disclosures.php and http://www.financialwire.net/2010/04/23/safe-harbor/). Additional resources for investors are also accessible via the FinancialWire(tm) website (at http://www.financialwire.net/2010/04/23/investor-resources/). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Copyright © MMX, FinancialWire(tm); All rights reserved.

[hlmsmlh] [biomedphrm] [ntrntnlcmpnsbsnss] [erpnpre] [ntrntnlcmpnsbsnss] [prtnrshpsphs] [ftrdnwswnd]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.